Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia - Concepedia

Concepedia

Publication | Closed Access

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

653

Citations

17

References

2014

Year

Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier, Petra Klappers, Matthias Stelljes, Svenja Neumann, Andreas Viardot, Reinhard Marks, H. Diedrich, Christoph Faul,

Journal of Clinical Oncology

Abstract

The data support further investigation of blinatumomab for the treatment of adult patients with relapsed or refractory ALL in a larger confirmatory study.

References

	Year	Citations

Page 1